Innate immunity against Leishmania infections

Cellular Microbiology

Volumn 17, Issue 9, 2015, Pages 1286-1294

  Gurung, Prajwal ^a   Kanneganti, Thirumala Devi ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Complement; Leishmania; NLR; TLR

Indexed keywords

COMPLEMENT; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR;

ANTIGEN RECOGNITION; COMPLEMENT SYSTEM; HOST PARASITE INTERACTION; HUMAN; IMMUNE EVASION; INNATE IMMUNITY; LEISHMANIA; LEISHMANIASIS; NONHUMAN; PARASITE IMMUNITY; PARASITE VIRULENCE; PRIORITY JOURNAL; SHORT SURVEY; IMMUNOLOGY;

HUMANS; IMMUNITY, INNATE; LEISHMANIA; LEISHMANIASIS;

EID: 84940435295     PISSN: 14625814     EISSN: 14625822     Source Type: Journal    
DOI: 10.1111/cmi.12484     Document Type: Short Survey

References (91)

1. Alvar, J., Velez, I.D., Bern, C., Herrero, M., Desjeux, P., Cano, J., et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671.
2. Becker, I., Salaiza, N., Aguirre, M., Delgado, J., Carrillo-Carrasco, N., Kobeh, L.G., et al. (2003) Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol 130: 65-74.
3. Belkaid, Y., Kamhawi, S., Modi, G., Valenzuela, J., Noben-Trauth, N., Rowton, E., et al. (1998) Development of a natural model of cutaneous Leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 188: 1941-1953.
4. Belkaid, Y., Mendez, S., Lira, R., Kadambi, N., Milon, G. and Sacks, D. (2000) A natural model of Leishmania major infection reveals a prolonged 'silent' phase of parasite amplifcation in the skin before the onset of lesion formation and immunity. J Immunol 165: 969-977.
5. Brittingham, A., Morrison, C.J., McMaster, W.R., McGwire, B.S., Chang, K.P. and Mosser, D.M. (1995) Role of the Leishmania surface protease gp63 in complement fixation, cell adhesion, and resistance to complement-mediated lysis. J Immunol 155: 3102-3111.
6. Bryson, K.J., Wei, X.Q. and Alexander, J. (2008) Interleukin-18 enhances a Th2 biased response and susceptibility to Leishmania mexicana in BALB/c mice. Microbes and infection / Institut Pasteur 10: 834-839.
7. Capul, A.A., Hickerson, S., Barron, T., Turco, S.J. and Beverley, S.M. (2007) Comparisons of mutants lacking the Golgi UDP-galactose or GDP-mannose transporters establish that phosphoglycans are important for promastigote but not amastigote virulence in Leishmania major. Infect Immun 75: 4629-4637.
8. Carter, C.R., Whitcomb, J.P., Campbell, J.A., Mukbel, R.M. and McDowell, M.A. (2009) Complement receptor 3 deficiency influences lesion progression during Leishmania major infection in BALB/c mice. Infect Immun 77: 5668-5675.
9. CDC (2013) Center for Disease Control and Prevention. Parasites- Leishmaniasis. http://www.cdc.gov/parasites/leishmaniasis/epi.html Global Health - Division of Parasitic Diseases and Malaria.
10. Chandel, H.S., Pandey, S.P., Shukla, D., Lalsare, K., Selvaraj, S.K., Jha, M.K. and Saha, B. (2014) Toll-like receptors and CD40 modulate each other's expression affecting Leishmania major infection. Clin Exp Immunol 176: 283-290.
11. Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R.W., et al. (2007) Visceral Leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873-882.
12. David, C.V. and Craft, N. (2009) Cutaneous and mucocutaneous Leishmaniasis. Dermatol Ther 22: 491-502.
13. Davis, B.K., Wen, H. and Ting, J.P. (2011). The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 29: 707-735.
14. de Veer, M.J., Curtis, J.M., Baldwin, T.M., DiDonato, J.A., Sexton, A., McConville, M.J., et al. (2003) MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and toll-like receptor 2 signaling. Eur J Immunol 33: 2822-2831.
15. Debus, A., Glasner, J., Rollinghoff, M. and Gessner, A. (2003) High levels of susceptibility and T helper 2 response in MyD88-deficient mice infected with Leishmania major are interleukin-4 dependent. Infect Immun 71: 7215-7218.
16. Dominguez, M., Moreno, I., Lopez-Trascasa, M. and Torano, A. (2002) Complement interaction with trypanosomatid promastigotes in normal human serum. J Exp Med 195: 451-459.
17. Dunkelberger, J.R. and Song, W.C. (2010) Complement and its role in innate and adaptive immune responses. Cell Res 20: 34-50.
18. Faria, M.S., Reis, F.C., Azevedo-Pereira, R.L., Morrison, L.S., Mottram, J.C. and Lima, A.P. (2011) Leishmania inhibitor of serine peptidase 2 prevents TLR4 activation by neutrophil elastase promoting parasite survival in murine macrophages. J Immunol 186: 411-422.
19. Flandin, J.F., Chano, F. and Descoteaux, A. (2006) RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-gamma-primed macrophages. Eur J Immunol 36: 411-420.
20. Gallego, C., Golenbock, D., Gomez, M.A. and Saravia, N.G. (2011) Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis. Infect Immun 79: 2871-2879.
21. Garami, A. and Ilg, T. (2001) Disruption of mannose activation in Leishmania mexicana: GDP-mannose pyrophosphorylase is required for virulence, but not for viability. EMBO J 20: 3657-3666.
22. Green, P.J., Feizi, T., Stoll, M.S., Thiel, S., Prescott, A. and McConville, M.J. (1994) Recognition of the major cell surface glycoconjugates of Leishmania parasites by the human serum mannan-binding protein. Mol Biochem Parasitol 66: 319-328.
23. Guerra, C.S., Silva, R.M., Carvalho, L.O., Calabrese, K.S., Bozza, P.T. and Corte-Real, S. (2010) Histopathological analysis of initial cellular response in TLR-2 deficient mice experimentally infected by Leishmania (L.) amazonensis. Int J Exp Pathol 91: 451-459.
24. Gupta, P., Giri, J., Srivastav, S., Chande, A.G., Mukhopadhyaya, R., Das, P.K. and Ukil, A. (2014) Leishmania donovani targets tumor necrosis factor receptor-associated factor (TRAF) 3 for impairing TLR4-mediated host response. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 28: 1756-1768.
25. Gurung, P., Karki, R., Vogel, P., Watanabe, M., Bix, M., Lamkanfi, M. and Kanneganti, T.D. (2015a) An NLRP3 inflammasome-triggered Th2-biased adaptive immune response promotes Leishmaniasis. J Clin Invest 125: 1329-1338.
26. Gurung, P., Lukens, J.R. and Kanneganti, T.D. (2015b) Mitochondria: diversity in the regulation of the NLRP3 inflammasome. Trends Mol Med 21: 193-201.
27. Harton, J.A., Linhoff, M.W., Zhang, J. and Ting, J.P. (2002) Cutting edge: CATERPILLER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains. J Immunol 169: 4088-4093.
28. Hoover, D.L., Berger, M., Hammer, C.H. and Meltzer, M.S. (1985) Complement-mediated serum cytotoxicity for Leishmania major amastigotes: killing by serum deficient in early components of the membrane attack complex. J Immunol 135: 570-574.
29. Hoover, D.L., Berger, M., Nacy, C.A., Hockmeyer, W.T. and Meltzer, M.S. (1984a) Killing of Leishmania tropica amastigotes by factors in normal human serum. J Immunol 132: 893-897.
30. Hoover, D.L. and Nacy, C.A. (1984b) Macrophage activation to kill Leishmania tropica: defective intracellular killing of amastigotes by macrophages elicited with sterile inflammatory agents. J Immunol 132: 1487-1493.
31. Huang, L., Hinchman, M. and Mendez, S. (2015) Coinjection with TLR2 agonist Pam3CSK4 reduces the pathology of Leishmanization in mice. PLoS Negl Trop Dis 9: e0003546.
32. Ilg, T. (2000) Lipophosphoglycan is not required for infection of macrophages or mice by Leishmania mexicana. EMBO J 19: 1953-1962.
33. Ilg, T., Demar, M. and Harbecke, D. (2001) Phosphoglycan repeat-deficient Leishmania mexicana parasites remain infectious to macrophages and mice. J Biol Chem 276: 4988-4997.
34. Joshi, P.B., Kelly, B.L., Kamhawi, S., Sacks, D.L. and McMaster, W.R. (2002) Targeted gene deletion in Leishmania major identifies Leishmanolysin (GP63) as a virulence factor. Mol Biochem Parasitol 120: 33-40.
35. Kanneganti, T.D. (2015) The inflammasome: firing up innate immunity. Immunol Rev 265, 1-5.
36. Kanneganti, T.D., Ozoren, N., Body-Malapel, M., Amer, A., Park, J.H., Franchi, L., et al. (2006) Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440: 233-236.
37. Karmakar, S., Bhaumik, S.K., Paul, J. and De, T. (2012) TLR4 and NKT cell synergy in immunotherapy against visceral Leishmaniasis. PLoS Pathog 8: e1002646.
38. Kautz-Neu, K., Kostka, S.L., Dinges, S., Iwakura, Y., Udey, M.C. and von Stebut, E. (2011) IL-1 signalling is dispensable for protective immunity in Leishmania-resistant mice. Exp Dermatol 20: 76-78.
39. Kawai, T. and Akira, S. (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34: 637-650.
40. Kaye, P. and Scott, P. (2011) Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 9: 604-615.
41. Kedzierski, L. (2010) Leishmaniasis vaccine: where are we today? Journal of global infectious diseases 2: 177-185.
42. Kropf, P., Freudenberg, M.A., Modolell, M., Price, H.P., Herath, S., Antoniazi, S., et al. (2004a) Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect Immun 72: 1920-1928.
43. Kropf, P., Freudenberg, N., Kalis, C., Modolell, M., Herath, S., Galanos, C., et al. (2004b) Infection of C57BL/10ScCr and C57BL/10ScNCr mice with Leishmania major reveals a role for toll-like receptor 4 in the control of parasite replication. J Leukoc Biol 76: 48-57.
44. Laurenti, M.D., Orn, A., Sinhorini, I.L. and Corbett, C.E. (2004) The role of complement in the early phase of Leishmania (Leishmania) amazonensis infection in BALB/c mice. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica... [et al] 37: 427-434.
45. Law, S.K. (1988) C3 receptors on macrophages. J Cell Sci Suppl 9: 67-97.
46. Liese, J., Schleicher, U. and Bogdan, C. (2007) TLR9 signaling is essential for the innate NK cell response in murine cutaneous Leishmaniasis. Eur J Immunol 37: 3424-3434.
47. Lima-Junior, D.S., Costa, D.L., Carregaro, V., Cunha, L.D., Silva, A.L., Mineo, T.W., et al. (2013) Inflammasome-derived IL-1beta production induces nitric oxide-mediated resistance to Leishmania. Nat Med 19: 909-915.
48. Mariathasan, S., Newton, K., Monack, D.M., Vucic, D., French, D.M., Lee, W.P., et al. (2004) Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430: 213-218.
49. Mariathasan, S., Weiss, D.S., Newton, K., McBride, J., O'Rourke, K. Roose-Girma, M., et al. (2006). Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228-232.
50. Martinon, F., Burns, K. and Tschopp, J. (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10: 417-426.
51. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. and Tschopp, J. (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241.
52. McConville, M.J., Turco, S.J., Ferguson, M.A. and Sacks, D.L. (1992) Developmental modification of lipophosphoglycan during the differentiation of Leishmania major promastigotes to an infectious stage. EMBO J 11: 3593-3600.
53. Monteforte, G.M., Takeda, K., Rodriguez-Sosa, M., Akira, S., David, J.R. and Satoskar, A.R. (2000) Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous Leishmania major infection. J Immunol 164: 5890-5893.
54. Mosser, D.M., Burke, S.K., Coutavas, E.E., Wedgwood, J.F. and Edelson, P.J. (1986) Leishmania species: mechanisms of complement activation by five strains of promastigotes. Exp Parasitol 62: 394-404.
55. Mosser, D.M. and Edelson, P.J. (1984) Activation of the alternative complement pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages. J Immunol 132: 1501-1505.
56. Mosser, D.M. and Edelson, P.J. (1985) The mouse macrophage receptor for C3bi (CR3) is a major mechanism in the phagocytosis of Leishmania promastigotes. J Immunol 135: 2785-2789.
57. Muraille, E., De Trez, C., Brait, M., De Baetselier, P., Leo, O. and Carlier, Y. (2003) Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response. J Immunol 170: 4237-4241.
58. Murray, H.W., Berman, J.D., Davies, C.R. and Saravia, N.G. (2005) Advances in Leishmaniasis. Lancet 366: 1561-1577.
59. Murray, H.W., Zhang, Y., Zhang, Y., Raman, V.S., Reed, S.G. and Ma, X. (2013) Regulatory actions of toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver. Infect Immun 81: 2318-2326.
60. Navin, T.R., Krug, E.C. and Pearson, R.D. (1989) Effect of immunoglobulin M from normal human serum on Leishmania donovani promastigote agglutination, complement-mediated killing, and phagocytosis by human monocytes. Infect Immun 57: 1343-1346.
61. Paul, J., Karmakar, S. and De, T. (2012) TLR-mediated distinct IFN-gamma/IL-10 pattern induces protective immunity against murine visceral Leishmaniasis. Eur J Immunol 42: 2087-2099.
62. Pearson, R.D. and Sousa, A.Q. (1996) Clinical spectrum of Leishmaniasis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 22: 1-13.
63. Pearson, R.D. and Steigbigel, R.T. (1980) Mechanism of lethal effect of human serum upon Leishmania donovani. J Immunol 125: 2195-2201.
64. Puentes, S.M., Da Silva, R.P., Sacks, D.L., Hammer, C.H. and Joiner, K.A. (1990) Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9. J Immunol 145: 4311-4316.
65. Puentes, S.M., Dwyer, D.M., Bates, P.A. and Joiner, K.A. (1989) Binding and release of C3 from Leishmania donovani promastigotes during incubation in normal human serum. J Immunol 143: 3743-3749.
66. Puentes, S.M., Sacks, D.L., da Silva, R.P. and Joiner, K.A. (1988) Complement binding by two developmental stages of Leishmania major promastigotes varying in expression of a surface lipophosphoglycan. J Exp Med 167: 887-902.
67. Raman, V.S., Bhatia, A., Picone, A., Whittle, J., Bailor, H.R., O'Donnell, J., et al. (2010) Applying TLR synergy in immunotherapy: implications in cutaneous Leishmaniasis. J Immunol 185: 1701-1710.
68. Ramer-Tait, A.E., Lei, S.M., Bellaire, B.H. and Beetham, J.K. (2012) Differential surface deposition of complement proteins on logarithmic and stationary phase Leishmania chagasi promastigotes. J Parasitol 98: 1109-1116.
69. Reithinger, R., Dujardin, J.C., Louzir, H., Pirmez, C., Alexander, B. and Brooker, S. (2007) Cutaneous Leishmaniasis. Lancet Infect Dis 7: 581-596.
70. Rizvi, F.S., Ouaissi, M.A., Marty, B., Santoro, F. and Capron, A. (1988) The major surface protein of Leishmania promastigotes is a fibronectin-like molecule. Eur J Immunol 18: 473-476.
71. Sacks, D. and Noben-Trauth, N. (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858.
72. Sacks, D.L., Modi, G., Rowton, E., Spath, G., Epstein, L., Turco, S.J. and Beverley, S.M. (2000) The role of phosphoglycans in Leishmania-sand fly interactions. Proc Natl Acad Sci U S A 97: 406-411.
73. Schamber-Reis, B.L., Petritus, P.M., Caetano, B.C., Martinez, E.R., Okuda, K., Golenbock, D., et al. (2013) UNC93B1 and nucleic acid-sensing toll-like receptors mediate host resistance to infection with Leishmania major. J Biol Chem 288: 7127-7136.
74. Schleicher, U., Liese, J., Knippertz, I., Kurzmann, C., Hesse, A., Heit, A., et al. (2007) NK cell activation in visceral Leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs. J Exp Med 204: 893-906.
75. Shio, M.T., Christian, J.G., Jung, J.Y., Chang, K.P. and Olivier, M. (2015) PKC/ROS-mediated NLRP3 inflammasome activation is attenuated by Leishmania zinc-metalloprotease during infection. PLoS Negl Trop Dis 9: e0003868.
76. Spath, G.F., Epstein, L., Leader, B., Singer, S.M., Avila, H.A., Turco, S.J. and Beverley, S.M. (2000). Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. Proc Natl Acad Sci U S A 97: 9258-9263.
77. Spath, G.F., Garraway, L.A., Turco, S.J. and Beverley, S.M. (2003a) The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc Natl Acad Sci U S A 100: 9536-9541.
78. Spath, G.F., Lye, L.F., Segawa, H., Sacks, D.L., Turco, S.J. and Beverley, S.M. (2003b) Persistence without pathology in phosphoglycan-deficient Leishmania major. Science 301: 1241-1243.
79. Srivastav, S., Kar, S., Chande, A.G., Mukhopadhyaya, R. and Das, P.K. (2012) Leishmania donovani exploits host deubiquitinating enzyme A20, a negative regulator of TLR signaling, to subvert host immune response. J Immunol 189: 924-934.
80. Srivastava, S., Pandey, S.P., Jha, M.K., Chandel, H.S. and Saha, B. (2013) Leishmania expressed lipophosphoglycan interacts with toll-like receptor (TLR)-2 to decrease TLR-9 expression and reduce anti-Leishmanial responses. Clin Exp Immunol 172: 403-409.
81. Ueno, N., Bratt, C.L., Rodriguez, N.E. and Wilson, M.E. (2009) Differences in human macrophage receptor usage, lysosomal fusion kinetics and survival between logarithmic and metacyclic Leishmania infantum chagasi promastigotes. Cell Microbiol 11: 1827-1841.
82. Vargas-Inchaustegui, D.A., Tai, W., Xin, L., Hogg, A.E., Corry, D.B. and Soong, L. (2009) Distinct roles for MyD88 and toll-like receptor 2 during Leishmania braziliensis infection in mice. Infect Immun 77: 2948-2956.
83. Von Stebut, E., Ehrchen, J.M., Belkaid, Y., Kostka, S.L., Molle, K., Knop, J., et al. (2003) Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J Exp Med 198: 191-199.
84. Voronov, E., Dotan, S., Gayvoronsky, L., White, R.M., Cohen, I., Krelin, Y., et al. (2010) IL-1-induced inflammation promotes development of Leishmaniasis in susceptible BALB/c mice. Int Immunol 22: 245-257.
85. Wei, X.Q., Leung, B.P., Niedbala, W., Piedrafita, D., Feng, G.J., Sweet, M., et al. (1999) Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol 163: 2821-2828.
86. Wei, X.Q., Niedbala, W., Xu, D., Luo, Z.X., Pollock, K.G. and Brewer, J.M. (2004) Host genetic background determines whether IL-18 deficiency results in increased susceptibility or resistance to murine Leishmania major infection. Immunol Lett 94: 35-37.
87. Weinkopff, T., Mariotto, A., Simon, G., Hauyon-La Torre, Y., Auderset, F., Schuster, S., et al. (2013) Role of toll-like receptor 9 signaling in experimental Leishmania braziliensis infection. Infect Immun 81: 1575-1584.
88. Wilson, M.E. and Pearson, R.D. (1986) Evidence that Leishmania donovani utilizes a mannose receptor on human mononuclear phagocytes to establish intracellular parasitism. J Immunol 136: 4681-4688.
89. Woelbing, F., Kostka, S.L., Moelle, K., Belkaid, Y., Sunderkoetter, C., Verbeek, S., et al. (2006) Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J Exp Med 203: 177-188.
90. Xin, L., Li, K. and Soong, L. (2008) Down-regulation of dendritic cell signaling pathways by Leishmania amazonensis amastigotes. Mol Immunol 45: 3371-3382.
91. Yao, C., Gaur Dixit, U., Barker, J.H., Teesch, L.M., Love-Homan, L., Donelson, J.E. and Wilson, M.E. (2013) Attenuation of Leishmania infantum chagasi metacyclic promastigotes by sterol depletion. Infect Immun 81: 2507-2517.